Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Q2 Revenues Increase Sharply on Joint Venture Contribution

NEW YORK (GenomeWeb) – GeneNews today reported a 44-fold year-over-year increase in its second quarter revenues.

The Toronto-based molecular diagnostics company reported that for the three months ended June 30, its revenues rose to C$441,111 (US$592,137) from C$10,019 in the year-ago period. Royalty revenues made up all of GeneNews' revenues for the recently completed quarter and were up from C$7,472 a year ago. The firm had no test revenues for Q2 2014, compared to C$2,547 a year ago.

In a statement, GeneNews Executive Chairman James Howard-Tripp said that its joint venture, Innovative Diagnostic Laboratory, formed a year ago, processed more than 46,000 tests in the quarter, a greater-than-three-fold increase from the first quarter, and added that the growth has continued into the third quarter. During the second quarter, IDL had total revenues of C$1.9 million. GeneNews did not disclose the revenue contribution from IDL during the quarter.

GeneNews' net loss in the quarter was C$2.7 million, or C$.06 per share, compared to a net loss of C$1.9 million, or $.06 per share, a year ago. GeneNews used about 44 million shares to calculate its loss on a per-share basis in Q2 2014, compared to almost 34 million shares in the year-ago period.

The company said that the increase in its loss resulted primarily from its share of IDL's loss.

GeneNews slashed its R&D costs to zero from C$572,656 a year ago, while it trimmed its SG&A costs 8 percent year over year to C$1.3 million from C$1.2 million.

The company ended the quarter with C$545,916 in cash and cash equivalents. Subsequent to the end of Q2, it raised C$7.2 million in a private placement.

"Moving into the second half of 2014, menu expansion remains a key priority and we are in discussions with several entities with respect to in-licensing their products," Howard-Tripp said. "The addition of new tests to our ColonSentry, EarlyCDT-Lung and [Beckman Coulter's Prostate Health Index] offerings is a central component of the IDL model which is designed to help accelerate growth, stratify commercial risk and advance us down the pathway toward positive cash-flows and net profitability."

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.